8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Oct 23, 2008)

Filed October 23, 2008For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on October 23, 2008, to report its financial results for the third quarter of 2008. The filing primarily serves as a notification of the release of this information, which was disseminated through a press release and supplemental information on the company's website. Investors seeking details on the company's performance, such as revenue, earnings, and operational highlights for the quarter, would need to refer to the furnished exhibits (Press Release and Supplemental Information) rather than the 8-K itself. This report indicates that BMY is adhering to disclosure requirements by promptly informing the SEC and the public of its quarterly financial performance. The critical information for assessing BMY's standing lies within the accompanying press release and supplemental data, which contain the actual financial figures and management's commentary on the results and outlook. Investors should consult these exhibits for a comprehensive understanding of the third-quarter 2008 financial condition and operational results.

Key Highlights

  • 1Bristol-Myers Squibb (BMY) filed an 8-K on October 23, 2008, to report its Q3 2008 financial results.
  • 2The filing's primary purpose is to provide notice of the earnings release and make accompanying materials available.
  • 3Key financial details for Q3 2008 are contained in the furnished press release (Exhibit 99.1) and supplemental website information (Exhibit 99.2).
  • 4The 8-K itself does not contain the specific financial results but references the documents where they can be found.
  • 5Investors are directed to review Exhibits 99.1 and 99.2 for comprehensive Q3 2008 financial performance data and commentary.
  • 6The report confirms BMY's adherence to timely disclosure regulations for quarterly earnings.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide access to Bristol-Myers Squibb's financial results for the third quarter of 2008. It serves as a notification to the SEC and the public that the company has released its earnings information.

The actual financial results and detailed commentary are not directly included in the 8-K form itself. You will need to refer to the furnished exhibits: Exhibit 99.1 (the press release dated October 23, 2008) and Exhibit 99.2 (certain supplemental information posted on the company's website).

This 8-K filing is primarily a report of past financial results for the third quarter of 2008. Any outlook or future guidance would likely be detailed within the accompanying press release (Exhibit 99.1) or supplemental information (Exhibit 99.2), which should be consulted for such details.

When reviewing the press release and supplemental information, investors should look for key metrics such as revenue, net income, earnings per share (EPS), operating expenses, cash flow from operations, and any specific drug sales performance or pipeline updates that drove the quarterly results.